FDA grants two Rare Pediatric Disease Designations to our kidney gene therapy


31 August 2026

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to WTX-001, the kidney gene therapy developed by Walther Therapeutics, the foundation’s drug development company.

The designation came in two separate decisions: one for Lowe syndrome and one for Dent disease type 2, the two inherited kidney disorders caused by faults in the OCRL gene.

The FDA gives this designation to medicines in development for serious or life-threatening diseases that mainly affect children. If WTX-001 is one day approved, the company may be eligible for a priority review voucher, which can shorten the FDA’s review of a later medicine or be sold to fund further work.

“For the families, these designations are an acknowledgement from the FDA of something they have lived with for years,” says Sebastian Honoré.

WTX-001 is still in preclinical development. The team is working on manufacturing, safety and efficacy studies in preparation for a first clinical study.

All stories